A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.

ABSTRACT: The necessity to accurately predict recurrence and clinical outcome in early stage colorectal cancer (CRC) is critical to identify those patients who may benefit from adjuvant chemotherapy. Here, we developed and validated a gene-based risk-score algorithm for patient stratification and personalised treatment in early stage disease based on alterations in the secretion of metastasis-related proteins. A quantitative label-free proteomic analysis of the secretome of highly and poorly metastatic CRC cell lines with different genetic backgrounds revealed 153 differentially secreted proteins (fold-change >5). These changes in the secretome were validated at the transcriptomic level. Starting from 119 up-regulated proteins, a six-gene/protein-based prognostic signature composed of IGFBP3, CD109,

SUBMITTER: Robles J 

PROVIDER: S-EPMC9535096 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature